These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 28870657)

  • 21. Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network.
    Fitzpatrick T; Alsager K; Sadarangani M; Pham-Huy A; Murguía-Favela L; Morris SK; Seow CH; Piché-Renaud PP; Jadavji T; Vanderkooi OG; Top KA; Constantinescu C;
    Lancet Child Adolesc Health; 2023 Sep; 7(9):648-656. PubMed ID: 37390832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose.
    Berrington JE; Cant AJ; Matthews JN; O'Keeffe M; Spickett GP; Fenton AC
    Pediatrics; 2006 Apr; 117(4):e717-24. PubMed ID: 16549502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.
    Flanagan E; Gibson PR; Wright EK; Moore GT; Sparrow MP; Connell W; Kamm MA; Begun J; Christensen B; De Cruz P; Shelton E; Dowling D; Andrews JM; Brown SJ; Niewiadomski O; Ward MG; Rosella O; Rosella G; Kiburg KV; Ross AL; Bell SJ;
    Aliment Pharmacol Ther; 2020 Nov; 52(10):1551-1562. PubMed ID: 32981127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis.
    Bonovas S; Fiorino G; Allocca M; Lytras T; Nikolopoulos GK; Peyrin-Biroulet L; Danese S
    Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1385-1397.e10. PubMed ID: 27189910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
    Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
    Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age.
    Maertens K; Caboré RN; Huygen K; Vermeiren S; Hens N; Van Damme P; Leuridan E
    Vaccine; 2016 Jun; 34(31):3613-9. PubMed ID: 27142328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants.
    Granoff DM; Holmes SJ; Belshe RB; Osterholm MT; McHugh JE; Anderson EL
    JAMA; 1994 Oct; 272(14):1116-21. PubMed ID: 7933324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group.
    Schlesinger Y; Granoff DM
    JAMA; 1992 Mar; 267(11):1489-94. PubMed ID: 1538539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period.
    Miller MA; Meschievitz CK; Ballanco GA; Daum RS
    Pediatrics; 1995 Apr; 95(4):522-7. PubMed ID: 7700752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine.
    Eskola J; Olander RM; Hovi T; Litmanen L; Peltola S; Käyhty H
    Lancet; 1996 Dec 21-28; 348(9043):1688-92. PubMed ID: 8973430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
    Dhillon S
    BioDrugs; 2010 Oct; 24(5):299-302. PubMed ID: 20795752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparisons of the effect of naturally acquired maternal pertussis antibodies and antenatal vaccination induced maternal tetanus antibodies on infant's antibody secreting lymphocyte responses and circulating plasma antibody levels.
    Ahmad SM; Alam J; Afsar NA; Huda N; Kabir Y; Qadri F; Raqib R; Stephensen CB
    Hum Vaccin Immunother; 2016 Apr; 12(4):886-93. PubMed ID: 27176823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
    Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
    Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study.
    Khatami A; Snape MD; Wysocki J; John TM; Westcar S; Mesaros N; Peddiraju K; Boutriau D; Yu LM; Pollard AJ
    Pediatr Infect Dis J; 2012 Oct; 31(10):1069-73. PubMed ID: 22673139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of HIV-1 exposure and antiretroviral treatment strategies in HIV-infected children on immunogenicity of vaccines during infancy.
    Simani OE; Izu A; Violari A; Cotton MF; van Niekerk N; Adrian PV; Madhi SA
    AIDS; 2014 Feb; 28(4):531-41. PubMed ID: 24468996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants.
    Klein NP; Abu-Elyazeed R; Cornish M; Leonardi ML; Weiner LB; Silas PE; Grogg SE; Varman M; Frenck RW; Cheuvart B; Baine Y; Miller JM; Leyssen M; Mesaros N; Roy-Ghanta S
    Vaccine; 2017 Jun; 35(28):3564-3574. PubMed ID: 28536030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune responses in infants whose mothers received Tdap vaccine during pregnancy.
    Hardy-Fairbanks AJ; Pan SJ; Decker MD; Johnson DR; Greenberg DP; Kirkland KB; Talbot EA; Bernstein HH
    Pediatr Infect Dis J; 2013 Nov; 32(11):1257-60. PubMed ID: 23799518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanus-pertussis vaccine.
    Clemens JD; Ferreccio C; Levine MM; Horwitz I; Rao MR; Edwards KM; Fritzell B
    JAMA; 1992 Feb; 267(5):673-8. PubMed ID: 1731134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants.
    Kattah MG; Milush JM; Burt T; McCabe RP; Whang MI; Ma A; Mahadevan U
    Clin Transl Gastroenterol; 2018 Apr; 9(4):143. PubMed ID: 29618720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.